What Transition Bio does

Transition Bio is a privately held drug discovery platform company founded in 2020 and headquartered in Cambridge, Massachusetts with an operating entity in Cambridge, United Kingdom. The company is built around biomolecular condensate biology, a relatively new frontier in drug discovery focused on the membraneless cellular compartments that organize protein interactions and drive disease when dysregulated. Transition Bio develops the Condensomics platform, an end-to-end discovery engine that combines proprietary droplet microfluidics (PhaseScan high-throughput molecular screening), state-of-the-art cellular imaging, and a machine learning/AI engine trained on proprietary datasets. The platform is designed to identify and optimize small molecule therapeutics against intrinsically disordered proteins and other condensate-modulating targets that traditional structure-based drug discovery has been unable to address. The company positions itself as tackling targets historically considered "undruggable," with disclosed pipeline programs in MYC-driven cancers (lead YTHDC1 inhibitor program across AML, SCLC, and NSCLC) and neurodegenerative disease (TDP-43 program partnered with Voyager Therapeutics for ALS and frontotemporal dementia).

The company's core technology assets were developed through exclusive academic relationships with Harvard University's Weitz Laboratory and the University of Cambridge's Knowles Laboratory. Scientific co-founders include David Weitz (Harvard, h-index 218, NAS/NAE member), Tuomas Knowles (Cambridge, 300+ publications), Peter St George-Hyslop (Columbia, leading Alzheimer's researcher), and Sarah Teichmann (Wellcome Sanger Institute, co-leader of the Human Cell Atlas). Operating leadership includes Executive Chairman G. Kelly Martin (former CEO of Radius Health and Elan Corporation), CEO Gregory Miller, Co-President and CSO Shilpi Arora (formerly VP at Exo Therapeutics), and Co-President and COO Martin Kulander (formerly Senior/Executive Director at AstraZeneca). The board includes Voyager Therapeutics CEO Alfred W. Sandrock Jr., former CFO of Cerevel and Sangamo Kathy Yi, and a Northpond Ventures representative.

Transition Bio operates as a B2B partnership-driven drug discovery business rather than a product company. Revenue mechanics rely on milestone payments and royalties earned through co-development agreements with pharmaceutical and biotechnology partners. The company conducts discovery and lead optimization through development candidate nomination, at which point the partner typically obtains an exclusive license option for further development and commercialization. The most material disclosed partnership is the November 2025 Voyager Therapeutics collaboration on TDP-43, valued at up to $500 million in potential milestone payments plus royalties. Strategic investors include Bristol Myers Squibb, which participated in the 2022 Series A and represents a potential pharma partnership channel in addition to financial backing. To date, Transition Bio has raised approximately $63 million in disclosed funding (an undisclosed seed in 2020, a $50 million Series A in 2022 led by Northpond Ventures, and approximately $13.3 million in additional financing in October 2024), and has not disclosed product revenue.

Name

Transition Bio

Legal name

Transition Bio, LLC

Website

https://transitionbio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Transition Bio is a Cambridge, MA-based drug discovery platform company developing the Condensomics platform, combining droplet microfluidics, cellular imaging, and proprietary AI/ML to discover small molecules targeting biomolecular condensates and intrinsically disordered proteins for pharmaceutical and biotech partners.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Drug discovery platform
• Biomolecular condensates
• Droplet microfluidics
• Small molecule therapeutics
• Intrinsically disordered proteins

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing and Milestone Payments: Transition Bio generates revenue through partnership agreements where it receives milestone payments and royalties. The company is responsible for discovery and optimization until nomination of a development candidate, after which partners gain exclusive license options. The Voyager collaboration includes up to $500 million in milestone payments plus royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Transition Bio operates a drug discovery platform that partners with pharmaceutical and biotech companies to identify and optimize small molecule drug candidates against biomolecular condensate and intrinsically disordered protein targets. Through its proprietary Condensomics platform, which combines droplet microfluidics, advanced cellular imaging, and machine learning/AI, the company conducts target identification, hit identification, mechanism-of-action studies, and lead optimization through development candidate nomination, after which partners assume further development and commercialization via licensing arrangements.

Product overview

Transition Bio offers a unified Condensomics™ Platform for biomolecular condensate drug discovery, comprising PhaseScan screening technology (microfluidics-based high throughput molecular screening), a Machine Learning/AI engine (proprietary models for optimization), and pipeline programs including the YTHDC1 inhibitor program (lead oncology program targeting MYC-driven cancers) and TDP-43 collaboration (with Voyager for ALS/FTD). The platform integrates droplet microfluidics and cellular imaging with ML/AI to identify and optimize chemical matter for drug discovery.

Differentiator

Problem solved

Functional benefit

Products and services

• Condensomics Platform End-to-end condensate drug discovery platform that combines droplet microfluidics and state-of-the-art cellular imaging with machine learning and AI to discover and optimize small molecule drug candidates against biomolecular condensates and intrinsically disordered proteins. Offered to pharmaceutical and biotech partners through co-development agreements leading to development candidate nomination and licensing.
• YTHDC1 Inhibitor Program Lead small-molecule inhibitor program targeting YTHDC1 for MYC-driven cancers, including applications in small cell lung cancer (SCLC) and acute myeloid leukemia (AML). Lead candidate has demonstrated robust efficacy in MYC-driven cancers as a single agent and in combination with standard-of-care therapies.
• TDP-43 Drug Discovery Collaboration with Voyager Therapeutics Co-development program with Voyager Therapeutics to discover and develop small molecules targeting TDP-43 for ALS and frontotemporal dementia. Transition Bio handles discovery and optimization through development candidate nomination, after which Voyager gains an exclusive license option. Deal value up to $500 million in milestone payments plus royalties for Transition Bio.

Quantifiable outcome

• Up to $500 million in milestone payments plus royalties from Voyager partnership
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

One partnership is on record.

• Voyager TherapeuticscoreStrategic or Co-development Partner · 10 November 2025Collaboration to discover small molecules targeting TDP-43 for ALS and frontotemporal dementia. Transition Bio is responsible for discovery and optimization until nomination of a development candidate. Voyager gains exclusive license option upon candidate nomination. Deal includes up to $500M in milestone payments plus royalties for Transition Bio. The partnership addresses therapeutic challenges of targeting TDP-43, a protein involved in several neurodegenerative diseases.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Dewpoint Therapeutics: Closest direct competitor focused on discovering drugs that modulate biomolecular condensates. Both companies target intrinsically disordered proteins and condensate biology, addressing the same scientific thesis around condensates as druggable systems.
• Faze Medicines: Biomolecular condensate therapeutics company developing small-molecule condensate modulators. Directly comparable scientific platform and therapeutic thesis to Transition Bio's Condensomics engine.
• Nereid Therapeutics: Condensate biology-focused drug discovery company. Shares the same core scientific premise of targeting biomolecular condensates for difficult disease targets, with overlapping leadership and academic network.
• Insitro: AI/ML-driven drug discovery platform combining machine learning with high-throughput biology. Comparable platform-based business model targeting traditional and novel targets via proprietary computational infrastructure.
• Recursion Pharmaceuticals: Public AI-driven drug discovery platform combining high-throughput experimental biology with ML. Comparable partnership-driven model and platform approach to small-molecule discovery.
• Exscientia: AI-driven precision medicine company with end-to-end small-molecule discovery platform. Direct peer in AI-augmented drug discovery serving pharma partners via licensing and co-development deals.
• Atomwise: AI-driven small-molecule drug discovery company using proprietary ML for hit identification and lead optimization. Comparable partnership-based GTM motion serving pharma collaborators across multiple targets.

Broad incumbents

• Isomorphic Labs: Alphabet/DeepMind spinout applying AlphaFold-derived AI to drug discovery. Well-capitalized competitor in computational drug discovery with broader portfolio focus and strategic pharma partnerships (Novartis, Lilly).
• Schrödinger: Public computational chemistry and drug discovery company with physics-based simulation platform. Comparable technology-driven approach to small-molecule discovery and well-established pharma partnerships.

Emerging players

• Terray Therapeutics: AI-driven small-molecule discovery platform combining high-throughput experimentation with proprietary ML. Comparable platform approach at similar stage, focused on internal pipeline plus partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/transition-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transition Bio